


BOSTON SCIENTIFIC CORPORATION

ANNOUNCES ACQUISITION OF MINTEC


Natick, Mass. (May 3, 1996)--Boston Scientific Corporation
(NYSE:BSX) today announced the acquisition of MinTec Inc., a 
privately held company dedicated to the development of stent graft 
technology for the repair of diseased vessels and arteries.  The cash 
purchase price was approximately $70 million.

MinTec, headquartered in Freeport, Bahamas, has been pioneering the 
development of endovascular stent grafts for the repair of abdominal 
aortic aneurysms, peripheral aneurysms and peripheral vascular 
occlusive disease.  Boston Scientific will combine the MinTec 
proprietary stent technology platform and other BSC stent 
technologies with the unique vascular graft technology of its Meadox 
division to aggressively develop new devices for the emerging 
endovascular market.  These new endovascular devices will be 
marketed by both the Meadox (vascular surgery) and Medi-tech 
(interventional radiology) divisions of Boston Scientific.

Commenting on this most recent acquisition, Pete Nicholas, Chairman 
and Chief Executive Officer of Boston Scientific, said, "We have been 
working with MinTec for some time on the development of a unique 
bifurcated stent graft and delivery system for the endovascular repair 
of abdominal aortic aneurysms incorporating the Meadox graft 
technology.  We are excited by this collaboration and the combination 
of the two technology platforms and are anticipating an initial launch 
of a new generation device in the very near future."

Boston Scientific is a worldwide developer, manufacturer and 
marketer of medical devices whose products are used in a broad range 
of interventional medical specialties.


CONTACT:    Larry Best
Boston Scientific Corporation
508-650-8450


